Drawing for GLENERIC

USPTO serial 77783471

GLENERIC

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CAPSHAW, DANIEL
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GLENERIC?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Howard J. Shire

HOWARD J. SHIRE KENYON & KENYON LLP1 BROADWAYNEW YORK, NY 10004-1007UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals and Medicinal preparations, namely, opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for the treatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of painACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 14, 2012MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 14, 2012ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 15, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 14, 2011EX2GSOU EXTENSION 2 GRANTED—
Oct 13, 2011AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 12, 2011EXT2SOU EXTENSION 2 FILED—
Oct 12, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 9, 2011EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 7, 2011EX1GSOU EXTENSION 1 GRANTED—
Mar 7, 2011EXT1SOU EXTENSION 1 FILED—
Mar 7, 2011EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 12, 2010NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 17, 2010NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 17, 2010PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 9, 2010PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jul 8, 2010CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 9, 2010XAECEXAMINER'S AMENDMENT ENTERED—
Jun 9, 2010GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 9, 2010GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 9, 2010CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 5, 2010DMCCDATA MODIFICATION COMPLETED—
Jun 3, 2010ALIEASSIGNED TO LIE—
May 27, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 27, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 27, 2010ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Apr 27, 2010GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Apr 27, 2010GNSLLETTER OF SUSPENSION E-MAILED—
Apr 27, 2010CNSLSUSPENSION LETTER WRITTEN—
Apr 14, 2010TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 14, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 14, 2010TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 20, 2009GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 20, 2009GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 20, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 20, 2009DOCKASSIGNED TO EXAMINER—
Jul 22, 2009MPMKNOTICE OF PSEUDO MARK MAILED—
Jul 21, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 21, 2009NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance